Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Xeno Transplants's Enterprise Value for the quarter that ended in Mar. 2008 was $4.92 Mil.
Xeno Transplants's EBIT for the trailing twelve months (TTM) ended in Mar. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeno Transplants EV-to-EBIT Related Terms
Xeno Transplants EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Xeno Transplants's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xeno Transplants's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeno Transplants EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xeno Transplants's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Xeno Transplants's EV-to-EBIT falls into.
Xeno Transplants's current Enterprise Value is $0.00 Mil.
Xeno Transplants's EBIT for the trailing twelve months (TTM) ended in Mar. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeno Transplants (XENO) has a EV-to-EBIT of 0.00 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Xeno Transplants and its competitors.
Is Xeno Transplants' EV-to-EBIT too high?
Xeno Transplants' current EV-to-EBIT is 0.00.
How does Xeno Transplants' EV-to-EBIT compare to PRTX and GWSN?
Xeno Transplants' EV-to-EBIT of 0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 15.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Xeno Transplants and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeno Transplants's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeno Transplants stock overvalued right now?
Xeno Transplants (XENO) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Xeno Transplants (XENO), the current EV-to-EBIT is 0.00 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address143 Gardner Road, Brookline, MA, USA, 02445
Xeno Transplants Corp is a bio-technology research and development company, which intends to develop therapeutic applications of organs and cells derived from genetically engineered pigs as a transplant alternative to limited human donor sources.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XENO has been successfully added to your 
